Targeting HER2 beyond breast cancer

Mol Cell Oncol. 2019 Mar 20;6(3):1571984. doi: 10.1080/23723556.2019.1571984. eCollection 2019.


The structural basis of blocking human epidermal growth factor receptor-2 (HER2) dimerization remains of great interest to generate effective anti-cancer therapies. Despite clinically feasible outcome in mammary tumors, a fine consensus between efficacy and safety remains a critical challenge beyond breast cancer. Here we extrapolate on the balancing act using recently reported clinical findings in salivary ductal carcinomas.

Keywords: Targeted therapies; cancer; immunotherapy.